FY2025 · ended Dec 31, 2025 · Revenue $6.39M, +181.5% YoY · Filed Mar 12, 2026
Korro Bio, Inc. (KRRO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $6.4 million and a net loss of $117.3 million. Free cash flow was -$79.1 million. As of Jun 30, 2026 it held $137.9 million in cash and investments and $42.2 million in total debt.
Revenue (TTM)
$2.38M
Net income (TTM)
$-106.64M
-16.7% vs year-ago TTM
Operating cash flow (TTM)
$-67.95M
-1.0% vs year-ago TTM
Free cash flow (TTM)
$-68.27M
+7.6% vs year-ago TTM
EPS (TTM)
$-8.90
+8.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
14.42M
+53.6% vs prior year
Net cash
$95.71M
as of Jun 30, 2026
Operating margin
-4625.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KRRO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1703647
- Former names
- Frequency Therapeutics, Inc. (until Nov 6, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | — | $0 | $14.1M |
| Operating income | -$121.9M | -$91.9M | -$84.5M | -$59.0M | -$84.0M |
| Net income | -$117.3M | -$83.6M | -$81.2M | -$58.0M | -$84.7M |
| Diluted EPS | -$12.48 | -$9.37 | -$53.08 | — | — |
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M | -$53.6M | -$76.1M |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | -$58.8M | -$79.0M |
| Total assets | $113.5M | $226.2M | $221.7M | $73.7M | $185.4M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $8.9M | $54.5M |
| Stockholders' equity | $51.4M | $160.4M | $169.9M | -$99.0M | -$42.2M |
| Cash and investments | $85.2M | $163.1M | $166.2M | $67.5M | $142.4M |
| Total debt | $43.5M | $44.8M | $33.2M | $38.8M | $31.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Agreement ended, Results of operations
|
Nov 5, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Aug 19, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 830 Korro Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.